Basilea Pharmaceutica Ltd. announced that the sales of the antifungal Cresemba® in 2023 by its partner Knight Therapeutics Inc. in Latin America exceeded the threshold triggering the first sales milestone payment for this region.
Basilea Pharmaceutica Ltd. announced that the sales of the antifungal Cresemba® in 2023 by its partner Knight Therapeutics Inc. in Latin America exceeded the threshold triggering the first sales milestone payment for this region.